Patients with primary refractory or relapsed T-cell lymphoma typically have a poor prognosis and limited options for effective targeted therapy. This contrasts with the clinical success of using CD19-specific chimeric antigen receptors (CARs) in immunotherapies for B-cell malignancies. Thus, to begin to achieve the long- term goal of devising a CAR-T cell platform that can be safely and effectively applied in patients with T-cell lymphoma, new Project 2 has selected CD5 as a novel target antigen for CAR-transduced cells. This common surface marker of normal T cells is also expressed by an estimated 85% of T-cell malignancies and functions as a transmembrane inhibitory receptor that attenuates signaling from the antigen receptor of T cells and a subset of B cells. Importantly, CD5-specific CAR-T cell fratricide (self-killing) is limited in our experimental model, allowing the CAR-modified cells to expand normally, after which they display potent and selective cytotoxicity against malignant T cells. Nonetheless, we reasoned that a second target antigen might be helpful, as antigen loss during treatment is a major obstacle to truly successful therapy, in patients receiving CD19-specific CAR-T cells, for example. CD7 was judged the best candidate as it is expressed at a high level on >90% of T-lymphoblastic lymphomas and >60% of mature lymphomas including those lacking CD5. Although in preliminary studies CD7-specific CARs showed strong activity against CD7+ target cells, the transduced T cells did not rapidly downregulate CD7, leading to enhanced fratricide that abrogated further expansion. This pitfall was eliminated by targeted depletion of the antigen in the CAR-modified T cells, a step that did not compromise either expansion or antitumor activity. Given these positive findings, we hypothesize that CD5-specific CAR-T cells can be safely used to target CD5+ T-cell lymphomas and induce complete remissions, and that CD7- cells will continue to expand and function in even in the presence of CD7-directed CARs by T cells. We propose to test each strategy in the following specific aims.
Aim 1 : Manufacture the GMP-grade vector and develop the SOPs needed for a clinical trial of CD5-specific CAR-T cells in T-cell lymphoma, and obtain all necessary local and federal regulatory approval.
Aim 2 : Conduct and evaluate a clinical trial using CD5 CAR-T cells to induce remissions in individuals with residual T-cell lymphoma who would then become eligible for allogeneic stem cell transplant.
Aim 3 : Express the CD7-specific CAR on CD7- effector T cells as a means to increase the range of targetable tumors and overcome CD5 antigen escape. Our proposed studies of CD5-specific CARs and the preclinical development of a CD7-specific CAR will do much to substantiate and advance our CAR-based platform for the treatment of T-cell malignancies and would provide a scientific basis for further optimization.

Public Health Relevance

The success that has marked the use of immune-based therapies for B-cell malignancies has not yet extended to lymphomas of T-cell origin. The research proposed here seeks to narrow that gap by developing and testing novel strategies to eliminate malignant T cells that express the CD5 or CD7 target antigen, or both.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA126752-11
Application #
9354052
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2007-09-11
Project End
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
11
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
McLaughlin, Lauren P; Rouce, Rayne; Gottschalk, Stephen et al. (2018) EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132:2351-2361
McClain, Kenneth L; Picarsic, Jennifer; Chakraborty, Rikhia et al. (2018) CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 124:2607-2620
Gomes-Silva, Diogo; Ramos, Carlos A (2018) Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol J 13:
Brunetti, Lorenzo; Gundry, Michael C; Kitano, Ayumi et al. (2018) Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. J Vis Exp :
Xiong, Wei; Chen, Yuhui; Kang, Xi et al. (2018) Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther 26:963-975
Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Velasquez, Mireya Paulina; Bonifant, Challice L; Gottschalk, Stephen (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131:30-38

Showing the most recent 10 out of 270 publications